vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Hippo Holdings Inc. (HIPO). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $120.4M, roughly 1.4× Hippo Holdings Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 18.2%). Over the past eight quarters, Hippo Holdings Inc.'s revenue compounded faster (18.9% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.
ESPR vs HIPO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $120.4M |
| Net Profit | — | $6.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 5.6% |
| Net Margin | — | 5.0% |
| Revenue YoY | 143.7% | 18.2% |
| Net Profit YoY | — | -86.4% |
| EPS (diluted) | $0.32 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $120.4M | ||
| Q3 25 | $87.3M | $120.6M | ||
| Q2 25 | $82.4M | $117.3M | ||
| Q1 25 | $65.0M | $110.3M | ||
| Q4 24 | $69.1M | $101.9M | ||
| Q3 24 | $51.6M | $95.5M | ||
| Q2 24 | $73.8M | $89.6M | ||
| Q1 24 | $137.7M | $85.1M |
| Q4 25 | — | $6.0M | ||
| Q3 25 | $-31.3M | $98.1M | ||
| Q2 25 | $-12.7M | $1.3M | ||
| Q1 25 | $-40.5M | $-47.7M | ||
| Q4 24 | — | $44.2M | ||
| Q3 24 | $-29.5M | $-8.5M | ||
| Q2 24 | $-61.9M | $-40.5M | ||
| Q1 24 | $61.0M | $-35.7M |
| Q4 25 | 50.6% | 5.6% | ||
| Q3 25 | -11.4% | 81.3% | ||
| Q2 25 | 8.6% | 3.4% | ||
| Q1 25 | -34.0% | -41.3% | ||
| Q4 24 | -6.4% | 46.3% | ||
| Q3 24 | -31.0% | -5.4% | ||
| Q2 24 | 3.5% | -40.7% | ||
| Q1 24 | 52.5% | -38.7% |
| Q4 25 | — | 5.0% | ||
| Q3 25 | -35.9% | 81.3% | ||
| Q2 25 | -15.4% | 1.1% | ||
| Q1 25 | -62.2% | -43.2% | ||
| Q4 24 | — | 43.4% | ||
| Q3 24 | -57.2% | -8.9% | ||
| Q2 24 | -83.9% | -45.2% | ||
| Q1 24 | 44.3% | -42.0% |
| Q4 25 | $0.32 | $0.31 | ||
| Q3 25 | $-0.16 | $3.77 | ||
| Q2 25 | $-0.06 | $0.05 | ||
| Q1 25 | $-0.21 | $-1.91 | ||
| Q4 24 | $-0.14 | $1.81 | ||
| Q3 24 | $-0.15 | $-0.34 | ||
| Q2 24 | $-0.33 | $-1.64 | ||
| Q1 24 | $0.34 | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $218.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $436.1M |
| Total Assets | $465.9M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $218.3M | ||
| Q3 25 | $92.4M | $247.7M | ||
| Q2 25 | $86.1M | $198.9M | ||
| Q1 25 | $114.6M | $140.9M | ||
| Q4 24 | $144.8M | $197.6M | ||
| Q3 24 | $144.7M | $191.2M | ||
| Q2 24 | $189.3M | $175.9M | ||
| Q1 24 | $226.6M | $223.4M |
| Q4 25 | $-302.0M | $436.1M | ||
| Q3 25 | $-451.4M | $421.5M | ||
| Q2 25 | $-433.5M | $332.5M | ||
| Q1 25 | $-426.2M | $322.8M | ||
| Q4 24 | $-388.7M | $362.1M | ||
| Q3 24 | $-370.2M | $326.4M | ||
| Q2 24 | $-344.2M | $322.6M | ||
| Q1 24 | $-294.3M | $351.2M |
| Q4 25 | $465.9M | $1.9B | ||
| Q3 25 | $364.0M | $1.9B | ||
| Q2 25 | $347.1M | $1.7B | ||
| Q1 25 | $324.0M | $1.5B | ||
| Q4 24 | $343.8M | $1.5B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.5B | ||
| Q1 24 | $373.1M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $9.2M |
| Free Cash FlowOCF − Capex | — | $9.1M |
| FCF MarginFCF / Revenue | — | 7.6% |
| Capex IntensityCapex / Revenue | 0.0% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.53× |
| TTM Free Cash FlowTrailing 4 quarters | — | $14.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $9.2M | ||
| Q3 25 | $-4.3M | $16.9M | ||
| Q2 25 | $-31.4M | $24.7M | ||
| Q1 25 | $-22.6M | $-35.6M | ||
| Q4 24 | $-35.0M | $47.5M | ||
| Q3 24 | $-35.3M | $46.8M | ||
| Q2 24 | $-7.2M | $-10.6M | ||
| Q1 24 | $53.8M | $17.7M |
| Q4 25 | — | $9.1M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $24.6M | ||
| Q1 25 | — | $-35.7M | ||
| Q4 24 | — | $47.2M | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | $-10.7M | ||
| Q1 24 | $53.8M | $17.6M |
| Q4 25 | — | 7.6% | ||
| Q3 25 | — | 13.9% | ||
| Q2 25 | — | 21.0% | ||
| Q1 25 | — | -32.4% | ||
| Q4 24 | — | 46.3% | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | -11.9% | ||
| Q1 24 | 39.0% | 20.7% |
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.1% | 0.1% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | 19.00× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
HIPO
Segment breakdown not available.
